Overview
Intrahepatic cholestasis of pregnancy (ICP), often called “pregnancy‑related jaundice,” is a liver disorder that develops in the second or third trimester. It is characterized by impaired bile flow within the liver, leading to a buildup of bile acids in the maternal bloodstream. While the condition is typically benign for the mother, elevated fetal exposure to bile acids can increase the risk of preterm labor, fetal distress, and stillbirth.
- Who it affects: Primarily pregnant women, most commonly between 28–36 weeks gestation.
- Prevalence: Reported rates range from 0.2–2.0 % of pregnancies worldwide, with higher incidence in women of South‑Asian, Hispanic, and Scandinavian ancestry. In the United Kingdom, the prevalence is about 1 in 500 pregnancies, while in Chile and Norway it reaches up to 2 % [1][2].
Symptoms
Symptoms are usually mild at first and can be mistaken for normal pregnancy changes. They tend to worsen at night and improve after delivery.
- Itching (pruritus): The hallmark symptom. It typically starts on the palms of the hands and soles of the feet and may spread to the trunk, abdomen, and arms. The itch is often worse after a warm shower or at night.
- Jaundice (yellowing of skin and eyes): Visible in only 10–15 % of cases; the name “jaundice of pregnancy” is therefore somewhat misleading.
- Dark urine: Concentrated urine due to excess bilirubin excretion.
- Pale or clay‑colored stools: Indicates reduced bile pigment entering the intestine.
- Fatigue or malaise: General feeling of being unwell.
- Upper‑right abdominal discomfort: Rare, but some women report a dull ache near the liver.
Causes and Risk Factors
The exact trigger for ICP is unknown, but it is thought to be multifactorial, involving hormonal, genetic, and environmental components.
Hormonal influences
- Estrogen and progesterone rise dramatically in pregnancy; both can slow bile secretion.
- Elevated levels of progesterone metabolites (e.g., sulfated progesterone) have been shown to inhibit the liver’s bile transport proteins.
Genetic predisposition
- Mutations in the ABCB4 (MDR3) and ABCC2 (MRP2) genes, which encode proteins responsible for moving bile salts out of liver cells, increase susceptibility.
- Family history of ICP or of other cholestatic liver diseases raises risk 2–3‑fold.
Other risk factors
- Previous episode of ICP (recurrence rates up to 70 %).
- Multiple gestation (twins/triplets) – higher hormone levels.
- Maternal age >35 years.
- Pre‑existing liver disease (e.g., hepatitis, gallstones).
- Geographic and ethnic factors – higher rates in Chile, Norway, and among South‑Asian women living in the UK or USA.
- Use of oral contraceptives or hormone‑replacement therapy before pregnancy (potential priming effect).
Diagnosis
Because symptoms overlap with many harmless pregnancy changes, clinicians rely on laboratory testing and exclusion of other liver disorders.
Key laboratory tests
- Serum bile acids: Elevated fasting total bile acids >10 µmol/L confirm ICP. Levels >40 µmol/L are associated with higher fetal risk.
- Liver function tests (LFTs): Mild to moderate rises in alanine aminotransferase (ALT) and aspartate aminotransferase (AST); alkaline phosphatase is often high in pregnancy anyway, so it is less informative.
- Bilirubin: Total bilirubin may be mildly increased; marked elevation should prompt evaluation for other causes.
Additional investigations (to rule out alternatives)
- Viral hepatitis serologies (HBV, HCV).
- Autoimmune panels (ANA, anti‑smooth muscle antibodies) if autoimmune hepatitis is suspected.
- Ultrasound of the liver and gallbladder – looks for gallstones, biliary obstruction, or hepatic lesions.
Diagnostic criteria (simplified)
- Onset of pruritus in the second half of pregnancy, especially on palms/soles.
- Elevated fasting serum bile acids (>10 µmol/L) AND/OR abnormal LFTs.
- No other identifiable cause of liver dysfunction.
Treatment Options
Therapy aims to relieve maternal symptoms, lower serum bile‑acid concentrations, and reduce fetal risk. Treatment is individualized based on bile‑acid level, gestational age, and symptom severity.
Medications
- Ursodeoxycholic acid (UDCA): First‑line therapy. Dose 10–15 mg/kg /day, split into two doses. UDCA improves cholestasis, reduces itching, and modestly lowers bile‑acid levels. Meta‑analyses show decreased preterm birth rates and improved neonatal outcomes [3].
- Rifampicin: Considered second‑line when UDCA is insufficient. Dose 300 mg orally once daily, increased to 600 mg as needed. May further lower bile acids but requires liver‑function monitoring.
- Antihistamines / topical emollients: Helpful for symptom relief but do not treat the underlying cholestasis.
- Vitamin K supplementation: Recommended if prolonged prothrombin time is noted, because cholestasis can impair fat‑soluble vitamin absorption.
Procedures & Monitoring
- Fetal surveillance: Non‑stress tests (NST) twice weekly after 34 weeks, plus ultrasound for growth and amniotic fluid assessment.
- Early delivery: Many obstetricians recommend induction at 37–38 weeks for women with bile‑acid levels >40 µmol/L, balancing fetal maturity against stillbirth risk.
Lifestyle & Supportive Measures
- Cool showers or baths to soothe itching.
- Loose, breathable clothing; avoid wool and synthetic fabrics that trap heat.
- Topical moisturizers (e.g., 5% creams with menthol) applied after bathing.
- Stay hydrated and maintain a balanced diet; high‑protein meals may help liver function.
Living with Jaundice of Pregnancy (Intrahepatic Cholestasis of Pregnancy)
While the condition can be stressful, most women manage it successfully with proper care.
Daily management tips
- Track symptoms: Keep a diary of itch intensity (scale 0–10), timing, and any new signs like dark urine.
- Medication adherence: Take UDCA exactly as prescribed; missing doses can cause rapid rise in bile acids.
- Regular labs: Most clinicians repeat serum bile‑acid testing every 1–2 weeks.
- Stress reduction: Relaxation techniques (deep breathing, prenatal yoga) may lessen the perception of itch.
- Support network: Share your diagnosis with a partner, family, or a support group; emotional support improves outcomes.
Travel and work considerations
- Ask your obstetrician whether extended travel is safe; short trips are usually fine if you can keep cool and have access to medication.
- If you work in a hot environment, request accommodations (cooler workspace, frequent breaks).
Prevention
Because ICP is linked to genetics and pregnancy hormones, true primary prevention is limited. However, the following measures may reduce severity or lower the likelihood of a first episode:
- Pre‑pregnancy counseling: Women with a personal or family history of cholestasis should discuss risks with a hepatologist or maternal‑fetal medicine specialist.
- Weight management: Maintaining a healthy BMI (< 25 kg/m²) may lower hormone‑related stress on the liver.
- Avoid hepatotoxic substances: Limit alcohol, refrain from over‑the‑counter herbal supplements that lack safety data in pregnancy.
- Early prenatal screening: In high‑risk populations (e.g., South‑Asian descent, prior ICP), clinicians may order baseline liver tests in the second trimester.
Complications
If left untreated or inadequately monitored, ICP can lead to both maternal and fetal complications.
Maternal
- Severe pruritus affecting sleep and quality of life.
- Rare progression to acute fatty liver of pregnancy or hepatic failure (primarily when bile‑acid levels >100 µmol/L).
- Vitamin K deficiency → increased bleeding risk during delivery.
Fetal/Neonatal
- Preterm birth: Up to 30 % of pregnancies with ICP deliver before 37 weeks.
- Fetal distress: Elevated bile acids can cause abnormal heart‑rate patterns.
- Low birth weight / small‑for‑gestational‑age (SGA): Bile acids may impair placental function.
- Stillbirth: The most serious risk; studies show a 2– to 4‑fold increase when fasting bile‑acid levels exceed 40 µmol/L [4].
- Neonatal respiratory distress syndrome (RDS) if delivered early without steroids.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Sudden, severe abdominal pain or cramping
- Bleeding or spotting that is heavier than a light brown discharge
- Decreased fetal movements (fewer than 10 kicks in 2 hours)
- High fever (≥38 °C / 100.4 °F) or chills
- Rapid swelling of the hands, feet, or face (possible pre‑eclampsia)
- Jaundice that worsens quickly or is accompanied by confusion, dark urine, or light‑colored stools
These signs may indicate a complication such as preterm labor, placental insufficiency, or liver failure, which require urgent evaluation.
References
- Mayo Clinic. Intrahepatic cholestasis of pregnancy. https://www.mayoclinic.org. Accessed May 2026.
- Royal College of Obstetricians & Gynaecologists. “Intra‑hepatic cholestasis of pregnancy” Green‑top Guideline No. 43, 2020.
- Wong, V. et al. “Ursodeoxycholic acid for intrahepatic cholestasis of pregnancy: systematic review and meta‑analysis.” *British Journal of Obstetrics & Gynaecology*, 2021;128(5):625‑634.
- Chappell, L. et al. “Bile acid concentrations and stillbirth risk in intra‑hepatic cholestasis of pregnancy.” *American Journal of Obstetrics & Gynecology*, 2022;227(3):331‑338.
- CDC. “Pregnancy‑related liver disorders.” https://www.cdc.gov. Accessed May 2026.